Lilly introduces lower-cost Zepbound vials in the US

USA – Eli Lilly has launched high-dose vials of its weight-loss drug Zepbound (tirzepatide) at a US $150 discount compared to its auto-injector versions.

The new 7.5mg and 10mg vials join the previously released 2.5mg and 5mg options, making treatment more affordable for patients paying out-of-pocket.

The new vials are available for US $499 per month through LillyDirect, the company’s direct-to-consumer platform.

However, patients must purchase their own syringes. Lilly is also reducing the price of the 2.5mg vial from US $399 to US $349 and the 5mg vial from US $549 to US $499.

This move intensifies competition with Novo Nordisk’s Wegovy (semaglutide) in the growing obesity drug market.

The FDA’s recent decision to end supply shortages for both drugs means compounding pharmacies will soon be unable to sell copycat versions, affecting companies like Hims & Hers and WeightWatchers.

Lilly’s cardiometabolic health head, Patrik Jonsson, emphasized the need for better insurance coverage for obesity treatments.

He stated, “Lilly is committed to working with all parties to solve this problem and, in the meantime, we’ll continue to implement new options that improve affordability and availability.”

Despite strong growth, Lilly recently adjusted its 2024 revenue forecast due to weaker-than-expected Zepbound and Mounjaro sales. Zepbound sales rose 176% to US $1.91 billion, while Mounjaro increased 60% to US $3.53 billion in the last quarter of 2024.